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Interleukin-2 (IL-2) therapy has been demonstrated to induce responses in 10-20% of advanced melanoma and
renal cell carcinoma patients, which translates into durable remissions in up to half of the responsers. Unfortunately
the use of IL-2 has been associated with severe toxicity and death. It has been previously observed and reported
that IL-2 therapy causes a major drop in circulating levels of ascorbic acid (AA). The IL-2 induced toxicity shares
many features with sepsis such as capillary leakage, systemic complement activation, and a relatively non-specific
rise in inflammatory mediators such as TNF-alpha, C-reactive protein, and in advanced cases organ failure. Animal
models and clinical studies have shown rapid depletion of AA in conditions of sepsis and amelioration associated with
administration of AA (JTM 9:1-7, 2011). In contrast to other approaches to dealing with IL-2 toxicity, which may also
interfere with therapeutic effects, AA possesses the added advantage of having direct antitumor activity through
cytotoxic mechanisms and suppression of angiogenesis. Here we present a scientific rationale to support the assessment
of intravenous AA as an adjuvant to decrease IL-2 mediated toxicity and possibly increase treatment efficacy.
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The basis of cancer therapy is to identify/develop inter-
ventions that: a) selectively kill tumor cells while sparing
non-malignant cells; b) prevent development of tumor-
resistance; and c) act systemically to prevent relapse.
Theoretically, immunotherapy of cancer would achieve
all these aims. Selective killing of tumor cells has been
demonstrated by a wide range of immune cells ranging
from conventional CD8 T cells, gamma delta T cells, nat-
ural killer (NK) cells, natural killer T (NKT) cells and in
some studies neutrophils. Other components of the im-
mune system expressing tumor selectivity include comple-
ment factors and natural antibodies of the IgM isotype.
Tumor resistance to immunotherapy, differs from resist-
ance to chemotherapy, where expression of multiple drug
resistance proteins actively pumps out cancer-toxic sub-
stances. One mechanism is downregulation of human
leukocyte antigen (HLA) by tumor cells in response to
T cell killing. The immune system conceptually overcomes* Correspondence: samuel.wagner@batubiologics.com
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unless otherwise stated.this by the NK subset which preferentially kills cells with
downregulated HLA. The other mechanism of tumor re-
sistance from immunological attack is by mutating anti-
gens that are being recognized. Given the promiscuous
binding ability of T cell and B cell receptors to bind anti-
gens, the cells could conceptually “mutate with the tumor”
in order to recognize and kill cells with variant antigens.
Immunological destruction of neoplasia is believed to
occur at a systemic level and thus arises the possibility to
inhibit metastasis and tumor recurrence, in part through
induction of immunological memory.
The history of tumor immunotherapy begins with the
work of William Coley who induced a systemic inflam-
matory/immune activation through administration of
killed S. pyogenes and Serratia marcescens bacteria in
patients with soft tissue sarcoma [1]. The advent of mo-
lecular biology allowed for assessment of molecular sig-
nals associated with systemic immune activation. The
cytokine tumor necrosis factor (TNF)-alpha was one of
the molecular signals associated with anticancer efficacy
of innate immune activators such as the Coley vaccinel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ability to induce profound death of cancer cells in vitro
and in vivo in animal models, however human studies
demonstrated unacceptable levels of toxicity [3-5]. IL-2
was the next cytokine associated with immune activation
that was tested. Originally termed T Cell Growth Factor
(TCGF) [6], IL-2 was demonstrated in early studies to
endow human lymphocytes with ability to selectively kill
tumor but not healthy control cells [7]. Subsequent
studies have demonstrated that cytotoxic activity was
mediated through T cell and natural killer (NK) cells,
whose activation requires stimulation of the IL-2 recep-
tor [8,9], which can be accomplished in vivo with high
doses of IL-2 [10-12]. Animal studies suggested that IL-
2 has a short half-life of approximately 2 minutes after
intravenous injection [13,14], and human half life was
reported to be approximately an hour [15]. Thus it was
apparent that clinical use of IL-2 would be requiring
repeated administration at high doses. Despite this
pitfall, preclinical studies demonstrated highly potent
anti-tumor effect. In 1985 Steven Rosenberg reported
regression of established pulmonary metastasis, as well
as various subcutaneous tumors by administration of
IL-2 [16]. These data were highly promising due to the
fact that tumor killing could be achieved systemically,
and by activation of specific immune cells that could
be identified in vivo as interacting with and inducing
death of the tumor.
Early studies of IL-2 demonstrated impressive results
in a subset of melanoma and renal cell cancer patients.
Development of systemic autoimmunity to melanocytes,
such as the occurence of vitiligo during the treatment with
systemic IL-2 was found to be predictive of response.
These studies were expanded and eventually IL-2 received
approval as the first recombinant immunotherapeutic
drug by the FDA. There appears to be a dose response
with IL-2 in that the doses that seem to be most effective
are also associated with significant toxicity. The most sig-
nificant cause of toxicity is vascular leak syndrome (VSL),
manifested as fluid loss into the interstitial space, which is
a result of increase vessel permeability. Additional effects
include thrombocytopenia, elevated hepatic serum trans-
aminases, hepatocyte necrosis, hypoalbuminemia, tissue
and peripheral eosinophilia, and prerenal azotemia [17].
Vascular leak syndrome
Vascular leak syndrome (VLS) is considered to be the
major dose-limiting adverse effect of IL-2 administra-
tion. In a meta-analysis of studies performed in meta-
static renal cell carcinoma patients, objective responses
were observed in 23% of patients, the majority of which
lasted more than 10 years [18]. Unfortunately, 65% of
patients have to interrupt or stop therapy because of
VLS [19,20]. This syndrome is characterized by anincreased extracellular fluid extravasation, hypotension,
ascites, pulmonary edema, and hydrothorax [21,22], and
clinically resembles the systemic inflammatory response
syndrome (SIRS). Dermatological manifestations include
erythrematous eruptions and mild papillary edema as-
sociated with burning and pruritus of the skin [23,24].
Severe forms of VLS are associated with pulmonary or
cardiac failure with approximately 1% of treated pa-
tients having lethal outcome. Typically the symptoms
of VLS are treated by vasopressor therapy and judicious
fluid replacement, such as with colloid solutions for
their osmotic effects. Patients may also be treated with
theophylline and terbutaline, for which clinical experi-
ence suggests a possible reduction of the severity and
frequency of acute episodes [25].
Mechanisms of VLS
Endothelial activation
At a cellular level it is well-known that VLS is associated
with endothelial cell activation and increased with vascu-
lar permeability. Biopsies of patients receiving IL-2 re-
vealed an increased expression of adhesion molecules
such as ICAM and LFA-1. These proteins are known to
promote granulocyte extravasation, however, such up-
regulation was not observed when IL-2 was added dir-
ectly to endothelial cell cultures in vitro, suggesting the
effect was mediated by other host components [26].
Given that one of the main cellular targets of IL-2 is the
T cells, which express two types of IL-2 receptor, it ap-
pears that the initial T cell activation is a major contribu-
tor to downstream inflammatory effect on endothelium
subsequent to IL-2 administration. In an early study,
Rosenberg’s group established a murine model for quanti-
fying VLS by administering radioactively iodinated albu-
min into mice receiving IL-2 and assessing radioactivity of
tissues, In this model, increased gamma-counts are corre-
lated with endothelial permeability and leakageof albumin
into tissues. They found that administration of IL-2 to
nude mice or mice that have been immune suppressed by
radiation, cyclophosphamide, or steroids, was associated
with markedly reduced or no vascular leakage [27].
T cells and nk cells contribute to endothelial activation
It is possible that the process of LAK generation is in-
volved in stimulation of VLS, as was suggested in a study
using a similar system in which transfer of LAK along
with administration of IL-2 led to more profound endo-
thelial leakage as compared to either alone. Interestingly,
in the same study it was shown that depletion of host
lymphocytes reduced vascular leakage only in response
to IL-2 alone, but not in response to IL-2 and LAK
transfer [28]. Other studies have shown that cells bear-
ing the NK marker asialo-GM1 are associated with some
of the IL-2 associated toxicities. Anderson et al showed
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lar leak syndrome, hepatic damage and reduced infiltration
of pulmonary and hepatic vasculature by asialo GM1+
lymphocytes induced by IL-2 treatment. Depletion of the
Asialo-GM1 bearing cells did not alter lymphoid hyperpla-
sia, tissue infiltration by Lyt 2+ lymphocytes, tissue and
peripheral eosinophilia, or thrombocytopenia. Interestingly,
the antisera did not affect the anti-tumor efficacy of IL-2
therapy in BDF mice bearing the colon 38 adenocarcinoma
[29]. Thus it is possible that T cell and NK cell activation
by the high dose IL-2 induces production of various cyto-
kines, one example being TNF-alpha [30], which are
known to induce endothelial cell activation locally [31],
and systemically are mediators of SIRS [32].
Complement activation
Another event associated with IL-2 administration appears
to be complement activation. The complement system
is an enzymatic cascade of about 30 circulating proteins,
primarily generated by the liver that cause inflammation
and amplification of a various immune responses. The
complement system can be activated through the classical
(antibody mediated) pathway, alternative pathways (anti-
body-independent), or through the mannose-binding
lectin pathway, all of which lead to formation of the
membrane attack complex which causes cell lysis through
generation of pores in the cell membrane [33]. In a clinical
study of metastatic renal cancer patients receiving IL-2 via
a 24-hour i.v. infusion at a daily dose of 3 × 10(6) U/m2
for 5 consecutive days, the classical complement pathway
components C3 and C4 were measured daily during IL-2
infusion, and after its interruption. IL-2 administration
was associated with a significant decrease in both C3
and C4 levels, which normalized on average 5 days after
the end of IL-2 infusion [34]. Another study associated
presence of VLS in patients receiving IL-2 with comple-
ment activation as assessed by levels of C3a and the
classical complement component C4a. In this study levels
of C3a were as elevated as those found in septic and burn
patients [35]. Another study examining 23 cancer patients
undergoing therapy with interleukin-2 and lymphokine-
activated killer cells demonstrated 3-fold elevations of
C3a desArg concentrations by the 8th day of therapy
with concentrations of C4a desArg also being elevated
by the end of therapy. Associated with activation of the
complement system was an increase in the neutrophil
cell-surface expression of complement receptor Type 1
and complement receptor Type 3 [36].
This interesting dependence on T cells for comple-
ment activation bridges the studies demonstrating that
T cells are necessary for both endothelial activation and
VLS associated with IL-2 administration. A study by
Vachino et al showed that cancer patients had pretreat-
ment similar to control plasma levels of C3a, Ba, Bb,and SC5b-9. Post-IL-2 treatment C3a levels where
shown to be increased on average of 15.6-fold (is this
differential from controls?). The Ba and Bb proteins,
which belong to the alternatively complement activa-
tion pathway were augmented 8.0- and 5.0-fold, re-
spectively, subsequent to IL-2 treatment. The plasma
levels of the effector complement complex, SC5b-9,
was increased 5.0-fold and the plasma C4d and iC3b
concentrations increased 4.8- and 2.9-fold, respectively,
after treatment. To show the involvement of patient
lymphocytes in complement activation, the investiga-
tors found that cells expressing the T cell marker CD3
had increased surface expression of anti-C3c and anti-
SC5b-9 by 6.2-fold and 5.1-fold, respectively after IL-2
therapy. The authors concluded that the T cells were
participating in the IL-2 induced complement activa-
tion. This was also demonstrated in that increased con-
centration of the inflammatory protein C-reactive
protein (CRP) was found post-IL-2 therapy [37], and
that the T cells bound CRP. T cell bound CRP was capable
of activating the alternative complement pathway [38].
Therapeutically, it was demonstrated that administration
of the complement inhibitor C1 esterase inhibitor was
capable of reducing IL-2 induced hypotension and com-
plement activation in patients [39,40].Complement activates endothelial cells
Various components of the complement cascade have
been demonstrated to directly activate endothelial cells,
with endothelial cell activation not only causing lympho-
cyte and neutrophil extravasation, but also thrombosis
by the upregulation of tissue factor [41]. C5a is a byproduct
of complement activation that has been demonstrated to
induce endothelial cell activation and permeability [42-45].
This protein is also a major effector in systemic inflamma-
tory disorders and antibodies to it are being assessed clinic-
ally for this condition with some efficacy signals and
suppression of endothelial activation published [46,47].
The complement effector complex SC5b-9 was demon-
strated in vitro to induce endothelial cell activation via
stimulating expression of the Response Gene to Comple-
ment (RGC)-32, which in turn activates CDC2 and the
AKT pathway [48]. Jeffrey Platt’s group demonstrated that
complement activation is associated with induction of IL-1,
which in turn stimulates endothelial cells expression of E-
selectin, intracellular adhesion molecule-1, vascular cell ad-
hesion molecule-1, Ikappa-Balpha, interleukin (IL)-1alpha,
IL-1beta, IL-8, and tissue factor [49]. Thus in the cascade
of IL-2 induced VLS, it appears that T cell activation may
be associated with complement activation, and comple-
ment activation, in turn, stimulates endothelial cell activa-
tion. One of the cardinal features of endothelial cell
activation is stimulation of the clotting cascade.
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According to the emerging picture that VLS has many
common elements with SIRS, one of the common features
is development of local thrombocyte and coagulation sys-
tem activation. Innate immune response possesses the
ability to locally marginalize pathogens by stimulation
of clotting and consequent sequestration. However, this
process becomes pathological when it occurs at a sys-
temic level, such as SIRS or VLS. Upregulation of tissue
factor expression was previously noted on endothelial
cells from animals treated with IL-2 [50]. Expression of
this protein is known to cause activation of the clotting
cascade, as well as stimulate inflammatory processes.
Hack et al demonstrated activation of the contact sys-
tem of coagulation proteins by showing that patients
on IL-2 therapy had degradation of factor XII and pre-
kallikrein. Reductions in these proteins appeared not
due to protein leakage into the interstitial space, since
their levels were still significantly lower, i.e., 80 and
50%, respectively, when corrected for albumin de-
creases (endothelium may still be more permeable to
these clotting factors than to albumin, that’s why i
would prefer “appeared”) [51]. Thus it appears that
non-specific activation of the coagulation system, and a
resulting potential for thrombosis, occur as a result of
IL-2 treatment. Given the inherently pro-thrombotic
state of many cancer patients, it is theoretically possible
that IL-2 therapy may have thrombotic complications,
which indeed have previously been reported [52].Granulocytes
Granulocyte activation and tissue infiltration are hall-
marks of systemic immune/inflammatory activation. In
a study of 4 patients on IL-2, granulocytes became acti-
vated following IL-2 treatment with mean peak elas-
tase/alpha 1-antitrypsin (E alpha 1 A) and lactoferrin
values of 212 (SEM = 37) and 534 (SEM = 92) ng ml-1
respectively occurring 6 h after the IL-2. Activation of
the complement cascade was evidenced by a dose
dependent elevation of peak C3a values on day 5 of IL-
2. The authors found that there was a significant correl-
ation between C3a levels and the degree of hypotension
during the first 24 h after IL-2 (r = 0.91) and parameters
of capillary leakage such as weight gain and fall in
serum albumin (r = 0.71). The authors concluded that
activation of PMN initiates endothelial cell damage
which subsequently leads to activation of the comple-
ment cascade [53]. Another study showed that neutro-
phils of patients on IL-2 therapy expressed both
phenotypic (up-regulation of CD11b/CD18 adhesion
receptor expression) and functional (hydrogen peroxide
and hypochlorous acid production) evidence of potent
neutrophil activation [54].Gut bacterial translocation
Gut bacterial translocation is associated with chronic in-
flammatory states such as heart failure [55] and mucosi-
tis [56], and acute states such as sepsis [57] or GVHD
[58], is translocation of bacterial flora into systemic cir-
culation. Interestingly, IL-2 toxicity is associated with an
interference with the gut flora and inflammation. In a
recent study, 51 male rats were randomized to receive
rIL-2 by intraperitoneal injection at doses (IU) of 10(5)
(n = 15), 10(4) (n = 8), 10(3) (n = 8) or 10(2) (n = 8)
twice daily, or a saline bolus (n = 12). After 5 days, ileal
histomorphology was assessed and the mesenteric
lymph node complex was cultured. Results showed that
colonisation of mesenteric lymph nodes with Escheri-
chia coli occurred in all rats treated with 10(5) IU of
rIL-2, and in 62%, 37% and 12% of rats treated with de-
creasing doses of rIL-2. No translocation was observed
in control animals. An increase in submucosal lym-
phatics and occasional mucosal disruption was seen
only in the group receiving 10(5) IU. These data show
that rIL-2 promotes bacterial translocation and suggests
a mechanism that may fuel high-dose rIL-2 toxicity in
humans [59]. Given the potent effects seen clinically
with homeostatically-induced lymphocyte activation
[60], and the recent findings that T cell homeostatic
proliferation appears to be associated with gut flora
translocation [61], it may be possible that tumor sup-
pressive activity of IL-2 may be highly dependent on
the gut flora, thus possibly explaining inter-patient
variation.
Oxidative stress
Numerous studies have demonstrated that oxidative
stress modifies endothelial cells in a manner that prefer-
entially activates the complement cascade [62]. The in-
volvement of the mannose-binding lectin and the lectin
complement pathway (LCP) in promoting complement
activation by endothelial cells post oxidative stress was
shown in studies using hypoxic (24 hours; 1% O(2))/
reoxygenated (3 hours; 21% O(2)) human endothelial
cells. Using iC3b deposition as a marker of complement
activation, it was shown that N-acetyl-D-glucosamine or
D-mannose, but not L-mannose, blocked activation, sug-
gesting that oxidative stress upregulates the mannose
dependent pathway. This was also demonstrated using
mannose binding lectin deficient serum, as well as anti-
bodies to mannose binding lectin. Furthermore C3 depos-
ition was found in ischemic areas in rats that experienced
cardiac ischemia reperfusion injury, a known inducer of
oxidative stress [63].
Vitamin C Depletion after IL-2 therapy
The initial stimulus for writing this review was inspired
by the observations made by two of the authors (DTA,
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oma patient treated with IL-2. The patient presented
with acute signs and symptoms of scurvy (perifollicular
petechiae, erythema, gingivitis and bleeding). Serum
ascorbate levels were significantly reduced to almost
undetectable levels during the treatment with IL-2
[64]. Although the role of ascorbic acid (AA) hyper-
supplementation in stimulation of immunity in healthy
subjects is controversial, it is well established that AA
deficiency is associated with impaired cell mediated
immunity. This has been demonstrated in numerous
studies showing that deficiency of this vitamin sup-
presses T cytotoxic responses, delayed type hypersensi-
tivity, and bacterial clearance [65]. Additionally, it is
well-known that NK activity, which mediates IL-2 anti-
tumor activity, is suppressed during conditions of AA
deficiency [66]. Thus it may be that while IL-2 therapy
on the one hand is stimulating T and NK function, the
systemic inflammatory syndrome-like effects of this
treatment may actually be suppressed by induction of a
negative feedback loop. This negative feedback loop
with IL-2 therapy was successfully overcome by work
using low dose histamine to inhibit IL-2 mediated im-
mune suppression, which led to the “drug” Ceplene
(histamine dichloride) receiving approval as an IL-2
adjuvant for treatment of AML [67].
The concept of AA deficiency subsequent to IL-2 ther-
apy was reported previously by another group. Marcus
et al evaluated 11 advanced cancer patients suffering
from melanoma, renal cell carcinoma and colon cancer
being on a 3 phase immunotherapeutic program consist-
ing of: a) 5 days of i.v. high-dose (10(5) units/kg every 8 h)
interleukin 2, (b) 6 1/2 days of rest plus leukapheresis; and
(c) 4 days of high-dose interleukin 2 plus three infusions
of autologous lymphokine-activated killer cells. Mean
plasma ascorbic acid levels were normal (0.64 +/- 0.25
mg/dl) before therapy. Mean levels dropped by 80% after
the first phase of treatment with high-dose interleukin 2
alone (0.13 +/- 0.08 mg/dl). Subsequently plasma ascorbic
acid levels remained severely depleted (0.08 to 0.13 mg/dl)
throughout the remainder of the treatment, becoming un-
detectable (less than 0.05 mg/dl) in eight of 11 patients
during this time. Importantly, blood pantothenate and
plasma vitamin E remained within normal limits in all 11
patients throughout the phases of therapy, suggesting the
hypovitaminosis was specific for AA. Strikingly, re-
sponders (n = 3) differed from nonresponders (n = 8) in
that plasma ascorbate levels in the former recovered to
at least 0.1 mg/dl (frank clinical scurvy) during Phases
2 and 3, whereas levels in the latter fell below this level
[68]. Similar results were reported in another study by
the same group examining an additional 15 patients
[69]. The hypothesis that prognosis was related to AA
levels is intriguing because of the possibility of higherimmune response in these patients, however this has
not been tested.
AA protects the endothelium from inflammation
The main cause of VSL is increased permeability of the
endothelium. Regardless of if the initiating cause is T cell
activation, complement, and/or oxidative stress, the ef-
fector mechanism of VLS is alteration of endothelial cell
function. In SIRS the endothelium is also the main ef-
fector causing lethality. Methods by which these cells
are altered by both SIRS and IL-2 include: a) endothelial
cell apoptosis, b )upregulation of adhesion molecules,
and c) increased procoagulant state [70].
It was shown that in vitro administration of AA led to
reduction of TNF-alpha induced endothelial cell apop-
tosis [71]. The effect was mediated in part through sup-
pression of the mitochondria-initiated apoptotic pathway
as evidenced by reduced caspase-9 activation and cyto-
chrome c release. Another study examined 34 patients
with NYHA class III and IV heart failure who received
AA or placebo treatment. AA treatment (2.5 g adminis-
tered intravenously and 3 days of 4 g per day oral AA)
resulted in reduction in circulating apoptotic endothelial
cells in the treated but this was not observed in the pla-
cebo control group [71]. Various mechanisms for inhib-
ition of endothelial cell apoptosis by AA have been
proposed including upregulation of the anti-apoptotic
protein bcl-2 [72] and the Rb protein, suppression of
p53 [73], and increasing numbers of newly formed endo-
thelial progenitor cells [74].
AA has been demonstrated to reduce endothelial cell
expression of the adhesion molecule ICAM-1 in re-
sponse to TNF-alpha in vitro in human umbilical vein
endothelial (HUVEC) cells (HUVEC) [75]. By reducing
adhesion molecule expression, AA suppresses systemic
neutrophil extravasation during sepsis, especially in the
lung [76]. Other endothelial effects of AA include sup-
pression of tissue factor upregulation in response to in-
flammatory stimuli [77], an effect expected to prevent
the hypercoaguable state. Furthermore, ascorbate sup-
plementation has been directly implicated in suppressing
endothelial permeability in the face of inflammatory
stimuli [78-80], which would hypothetically reduce vas-
cular leakage. Given the importance of NF-kappa B sig-
naling in coordinating endothelial inflammatory changes
[81-83], it is important to note that AA at pharmaco-
logically attainable concentrations has been demon-
strated to specifically inhibit this transcription factor in
endothelial cells [84]. Several pathways of inhibition have
been identified including reduction of i-kappa B phos-
phorylation and subsequent degradation [85], and sup-
pression of activation of the upstream p38 MAPK
pathway [86]. In vivo data in support of eventual use in
humans has been reported showing that administration
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in suppression of endothelial NF-kappa B activity, as
well as increased eNOS, NO, and endothelial function
[87]. In another porcine study, renal stenosis was com-
bined with a high cholesterol diet to mimic renovascular
disease. AA administered i.v. resulted in suppression of
NF-kappa B activation in the endothelium, an effect as-
sociated with improved vascular function [88].
AA Suppresses Systemic Inflammation
The possibility that IL-2 therapy induces a state of sys-
temic inflammation similar to SIRS has been discussed
previously. One of the fundamental questions is whether
AA actually has beneficial effects on the process of sys-
temic inflammation. A mouse study demonstrated that
after challenge with the bacteria Klebsiella pneumonia to
induce a sepsis-like state, a 3-fold higher mortality is ob-
served in ascorbate-deficient animals compared to con-
trols [89]. Another study hyper-supplemented animals
with AA by administration of 10 mg/kg AA intraven-
ously before induction of sepsis. IV AA treated animals
had a 50% survival while only 19% of control animals
survived [90]. Other studies demonstrated that hyper-
supplementation with AA resulted in better outcomes in
sepsis-associated hypoglycemia [91], microcirculatory
abnormalities [92], and blunted endothelial responsive-
ness [93-95] in animal models.
Randomized clinical trials have been performed in septic
patients using AA and vitamin E, which demonstrated su-
perior outcomes, as well as reduction in parameters of
oxidative stress [96,97]. To date we know of one study in
the recent history that assessed AA alone in patients with
systemic inflammation. The investigators examined
burn patients with > 30% of their total body surface area
affected. Patients were administered intravenous AA i.v.
(66 mg/kg/hr for 24 hours, n = 19) or received only
standard care (controls, n = 18). AA treatment resulted
in statistically significant reductions in 24 hr total fluid
infusion volume, and fluid retention (indicative of vas-
cular leakage). Perhaps most striking was the decrease
in the need for mechanical ventilation: the treated
group required an average of average of 12.1 ± 8.8 days,
while the control group required 21.3 ± 15.6 days [98].
Given that numerous inflammatory markers associated
with VLS are also found in SIRS and severe burn pa-
tients, the possibility is presented that AA may exert
some beneficial effects on IL-2 therapy, both from the
reduction of toxicity perspective, as well as from the
stimulation of efficacy.
Conclusion
We have previously reviewed the rationale for use of IV
AA in cancer patients, which includes direct tumor
cytotoxicity, antiangiogenic activities, and possibility ofincreasing quality of life. IL-2 therapy, although one of
the oldest successes of cancer immunotherapy, to date,
is still not widely implemented due to substantial asso-
ciated toxicity. To date one drug (Ceplene, histamine
dichloride) has succeeded the regulatory and clinical
threshold as an agent to reduce IL-2 toxicity and en-
hance efficacy, thus establishing a regulatory pathway
for development of such an agent. In contrast to
Ceplene, IV AA is commonly used in the treatment of
cancer patients by alternative medicine practitioners,
internationally and in the US. Several ongoing FDA
clinical trials are currently assessing IV AA as a mono-
therapy or adjuvant therapy in cancer [99-105]. The ra-
tionale that AA preserves endothelial function, inhibits
inflammation, and is effective in some states of systemic
inflammation, suggests that investigations showed be per-
formed at least in animal models. Our observation of a
scurvy-like state induced by IL-2 therapy, the correlation
between IL-2 levels and response to immunotherapy, and
the fact that IV AA is already clinically used in cancer pa-
tients, suggests that translation of the IV AA + IL-2 ther-
apy can be performed in a relatively rapid manner.
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